OncLive TV

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Kohei Shitara, MD, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric/gastroesophageal junction cancer.

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Jordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Myriam Chalabi, MD, highlights the importance of testing for microsatellite instability and mismatch repair deficiency in colorectal cancer.

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.